PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-50.43%
Negative net income growth while AVXL stands at 48.65%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
7.46%
Some D&A expansion while AVXL is negative at -0.40%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
46.91%
Deferred tax of 46.91% while AVXL is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
9.40%
SBC growth while AVXL is negative at -73.04%. John Neff would see competitor possibly controlling share issuance more tightly.
-262.74%
Negative yoy working capital usage while AVXL is 143.42%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-225.01%
Negative yoy AP while AVXL is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
155.76%
Growth well above AVXL's 143.42%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
9.40%
Some yoy increase while AVXL is negative at -8469.07%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-30.81%
Negative yoy CFO while AVXL is 41.41%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
49.68%
CapEx growth of 49.68% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Purchases growth of 100.00% while AVXL is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth of 100.00% while AVXL is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
82.07%
We expand invests by 82.07% while AVXL is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
-1.11%
We cut debt repayment yoy while AVXL is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
207.88%
We slightly raise equity while AVXL is negative at -92.58%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.